In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode * Variant vaccine boosters trial (medRxiv) * Novavax triggers neutralization of variant sub-lineages (bioRxiv) * CDC recommends Novavax (CDC) * Paxlovid in patients who are immunocompromised and hospitalized (The Lancet) * Inhaled Fluticasone for outpatient treatment (medRxiv) * PAXLOVID patient eligibility screening checklist (FDA) * Remdesivir fact sheet for providers (Veklury) * Bebtelovimab fact sheet for providers (FDA) * Contribute to FIMRC fundraiser at PWB * Dr. Griffin’s treatment guide (pdf) * Letters read on TWiV 921 * Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv